{"title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine", "author": "Sanofi Pasteur; A Sanofi Company", "url": null, "hostname": null, "description": null, "sitename": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine | ClinicalTrials.gov; 16/07/2021; TrialID: NCT04969276", "date": "2021-07-16", "cleaned_text": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine ClinicalTrials.gov; 16/07/2021; adverse events (AEs);Number of participants with solicited outcome: [injection site reactions]or systemic reactions;Number of participants with unsolicited AEs;Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs);Number of participants with medically attended adverse events (MAAE)s; [Hemagglutination]inhibition (HAI) individual titer;Individual HAI titers anti-S binding [IgG]concentration Criteria Inclusion Criteria - [Aged]= 65 years of age on the day of inclusion - In good [health]or with underlying medical condition(s) that are judged to be stable by the [Investigator]. A stable medical condition is defined as [disease]not requiring significant change in [therapy]or [hospitalization]for worsening [disease]during the 3 months before enrollment - Participants [who]previously received 2 [injections]of [Moderna COVID-19 Vaccine]with the second [dose]received at least 5 months before Visit 1 - Able to attend all scheduled visits and to comply with all study [procedures] Exclusion Criteria - Known or suspected [congenital]or acquired immunodeficiency; or receipt [radiation systemic [corticosteroid] [therapy] ( [prednisone]or equivalent for more than 2 consecutive weeks within the 3 months preceding planned inclusion) - Known systemic [hypersensitivity]to any of the study intervention components, or [history]of a [life]-threatening reaction to the study interventions used in the study or to a product containing any of the same substances - Previous [dermal filler] receipt of [anticoagulants]in the 3 weeks preceding inclusion, contraindicating IM [vaccination]. - [Chronic illness]that, in the [opinion]of the [Investigator], is at a stage where it might interfere with study conduct or completion - Moderate or severe acute illness/ [infection](according to [Investigator] [judgment]) on the febrile illness ( [temperature]= 100.4\u00b0F [38.0\u00b0C]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided - [History]of serious adverse reaction to any [influenza]or [COVID-19 vaccines] - Personal [history]of [Guillain-Barr\u00e9 syndrome](GBS) - Personal [history]of clinically significant developmental delay (at the discretion of the [Investigator]), [neurologic disorder], the [opinion]of the [Investigator]would pose a [health risk]to the participant if enrolled or could interfere with the evaluation of the [vaccine] - Receipt of any [vaccine]in the 4 weeks preceding the study intervention(s) [administration]or planned receipt of any [vaccine]in the period between V01 and 4 weeks following the study intervention(s) [administration]. Note [Vaccination]of Group 3 participants with Fluzone High- [Dose] [Quadrivalent vaccine]at the end of the study [will] not be considered by the Sponsor as meeting this exclusion criterion - Receipt of [blood]-derived [immune globulins], [blood], or [blood]-derived products in the past 3 months - Participation at the [time]of study enrollment (or in the 30 days preceding the first study [vaccination]) or planned participation during the present study period in another [clinical study]investigating [vaccine], [drug], [medical device], or medical [procedure] - Deprived of [freedom]by an administrative or court order, or in an [emergency]setting, or hospitalized involuntarily - Identified as an [Investigator]or [employee]of the [Investigator]or study center with direct involvement in the proposed study, or identified as an immediate [family member] (ie, [parent], [spouse], natural or [adopted child]) of the [Investigator]or [employee]with direct involvement in the proposed study - The above information is not intended to contain all considerations relevant to a [patient]'s potential participation in a [clinical Similares MEDLINE ... LILACS LIS "}